» Articles » PMID: 37535708

Females Display Relatively Preserved Muscle Quality Compared with Males During the Onset and Early Stages of C26-induced Cancer Cachexia

Abstract

Cancer cachexia is clinically defined by involuntary weight loss >5% in <6 mo, primarily affecting skeletal muscle. Here, we aimed to identify sex differences in the onset of colorectal cancer cachexia with specific consideration to skeletal muscle contractile and metabolic functions. Eight-weeks old BALB/c mice (69 males, 59 females) received subcutaneous C26 allografts or PBS vehicle. Tumors were developed for 10-, 15-, 20-, or 25 days. Muscles and organs were collected, in vivo muscle contractility, protein synthesis rate, mitochondrial function, and protein turnover markers were assessed. One-way ANOVA within sex and trend analysis between sexes were performed, < 0.05. Gastrocnemius and tibialis anterior (TA) muscles became atrophic in male mice at 25 days, whereas female mice exhibited no significant differences in muscle weights at endpoints despite presenting hallmarks of cancer cachexia (fat loss, hepatosplenomegaly). We observed lowered muscle contractility and protein synthesis concomitantly to muscle mass decay in males, with higher proteolytic markers in muscles of both sexes. mRNA of was lower in TA, whereas was higher in gastrocnemius after 25 days in male mice, with no significant effect in female mice. Our data suggest relative protections to skeletal muscle in females compared with males despite other canonical signs of cancer cachexia and increased protein degradation markers; suggesting we should place onus upon nonmuscle tissues during early stages of cancer cachexia in females. We noted potential protective mechanisms relating to skeletal muscle contractile and mitochondrial functions. Our findings underline possible heterogeneity in onset of cancer cachexia between biological sexes, suggesting the need for sex-specific approaches to treat cancer cachexia. Our study demonstrates biological-sex differences in phenotypic characteristics of cancer cachexia between male and female mice, whereby females display many common characteristics of cachexia (gonadal fat loss and hepatosplenomegaly), protein synthesis markers alterations, and common catabolic markers in skeletal muscle despite relatively preserved muscle mass in early-stage cachexia compared with males. Mechanisms of cancer cachexia appear to differ between sexes. Data suggest need to place onus of early cancer cachexia detection and treatment on nonmuscle tissues in females.

Citing Articles

Transcriptional analysis of cancer cachexia: conserved and unique features across preclinical models and biological sex.

Morena F, Cabrera A, Jones 3rd R, Schrems E, Muhyudin R, Washington T Am J Physiol Cell Physiol. 2024; 327(6):C1514-C1531.

PMID: 39466180 PMC: 11684872. DOI: 10.1152/ajpcell.00647.2024.


Withaferin A ameliorates ovarian cancer-induced renal damage through the regulation of expression of inflammatory cytokines.

Kumar K, Bosch K, Vemuri V, Kratholm N, Rane M, Kakar S J Ovarian Res. 2024; 17(1):199.

PMID: 39394174 PMC: 11468018. DOI: 10.1186/s13048-024-01519-9.


Mitochondrial antioxidant SkQ1 attenuates C26 cancer-induced muscle wasting in males and improves muscle contractility in female tumor-bearing mice.

Tsitkanou S, Morena da Silva F, Cabrera A, Schrems E, Muhyudin R, Koopmans P Am J Physiol Cell Physiol. 2024; 327(5):C1308-C1322.

PMID: 39344417 PMC: 11559642. DOI: 10.1152/ajpcell.00497.2024.


Decreased skeletal muscle intramyocellular lipid droplet-mitochondrial contact contributes to myosteatosis in cancer cachexia.

Cardaci T, VanderVeen B, Huss A, Bullard B, Velazquez K, Frizzell N Am J Physiol Cell Physiol. 2024; 327(3):C684-C697.

PMID: 39010842 PMC: 11427022. DOI: 10.1152/ajpcell.00345.2024.


Changes in skeletal muscle function during chemotherapy and related factors in patients with acute leukemia.

Terao Y, Nakayama Y, Abo M, Otobe Y, Suzuki M, Kojima I Support Care Cancer. 2024; 32(8):512.

PMID: 39001992 DOI: 10.1007/s00520-024-08729-3.


References
1.
Hain B, Xu H, Waning D . Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice. J Cachexia Sarcopenia Muscle. 2021; 12(6):1597-1612. PMC: 8718092. DOI: 10.1002/jcsm.12795. View

2.
Gorselink M, Vaessen S, van der Flier L, Leenders I, Kegler D, Caldenhoven E . Mass-dependent decline of skeletal muscle function in cancer cachexia. Muscle Nerve. 2005; 33(5):691-3. DOI: 10.1002/mus.20467. View

3.
Gasier H, Riechman S, Wiggs M, Previs S, Fluckey J . A comparison of 2H2O and phenylalanine flooding dose to investigate muscle protein synthesis with acute exercise in rats. Am J Physiol Endocrinol Metab. 2009; 297(1):E252-9. PMC: 4043319. DOI: 10.1152/ajpendo.90872.2008. View

4.
Hetzler K, Hardee J, Puppa M, Narsale A, Sato S, Davis J . Sex differences in the relationship of IL-6 signaling to cancer cachexia progression. Biochim Biophys Acta. 2015; 1852(5):816-25. PMC: 4372501. DOI: 10.1016/j.bbadis.2014.12.015. View

5.
Solheim T, Laird B, Balstad T, Bye A, Stene G, Baracos V . Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018; 8(3):258-265. DOI: 10.1136/bmjspcare-2017-001440. View